Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma

Cancer

Volumn 118, Issue 11, 2012, Pages 2952-2961

  Kao, Steven Chuan Hao ^a,b,c   Armstrong, Nicola ^d,e   Condon, Bridget ^h   Griggs, Kim ^g   McCaughan, Brian ^h   Maltby, Sarah ^f   Wilson, Alan ^f   Henderson, Douglas W ^f,g   Klebe, Sonja ^f,g  

^a Bernie Banton Centre   (Australia)

^b Department of Geriatric Medicine   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f FLINDERS UNIVERSITY   (Australia)

^g FLINDERS MEDICAL CENTRE   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

aquaporin 1; malignant mesothelioma; prognosis

Indexed keywords

AQUAPORIN 1;

ADULT; AGED; ANTIBODY LABELING; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL ACTIVITY; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM CELL; ONSET AGE; PATIENT CARE; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX RATIO; SURVIVAL RATE; TUMOR CELL; WATER TRANSPORT;

ADULT; AGED; AQUAPORIN 1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MICROSCOPY, IMMUNOELECTRON; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861337371     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26497     Document Type: Article

References (38)

1. Gatta G, Ciccolallo L, Kunkler I, et al. Survival from rare cancer in adults: a population-based study. Lancet Oncol. 2006; 7: 132-140.
2. Robinson BW, Musk AW, Lake RA,. Malignant mesothelioma. Lancet. 2005; 366: 397-408.
3. National Occupational Health and Safety Commission. The incidence of mesothelioma in Australia 1997 to 1999: Australian Mesothelioma Register report 2002. Canberra, Australia: National Occupational Health and Safety Commission; 2002.
4. Leigh J, Davidson P, Hendrie L, Berry D,. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med. 2002; 41: 188-201.
5. Zucali PA, De Vincenzo F, Simonelli M, Santoro A,. Future developments in the management of malignant pleural mesothelioma. Expert Rev Anticancer Ther. 2009; 9: 453-467.
6. Knepper MA,. The aquaporin family of molecular water channels. Proc Natl Acad Sci U S A. 1994; 91: 6255-6258.
7. Ishibashi K, Hara S, Kondo S,. Aquaporin water channels in mammals. Clin Exp Nephrol. 2009; 13: 107-117.
8. King LS, Agre P,. Pathophysiology of the aquaporin water channels. Annu Rev Physiol. 1996; 58: 619-648.
9. Verkman AS,. Physiological importance of aquaporin water channels. Ann Med. 2002; 34: 192-200.
10. Verkman AS, Matthay MA, Song Y,. Aquaporin water channels and lung physiology. Am J Physiol Lung Cell Mol Physiol. 2000; 278: L867-L879.
11. Borok Z, Verkman AS,. Lung edema clearance: 20 years of progress: invited review: role of aquaporin water channels in fluid transport in lung and airways. J Appl Physiol. 2002; 93: 2199-2206.
12. Woo J, Lee J, Chae YK, et al. Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett. 2008; 264: 54-62.
13. King LS, Nielsen S, Agre P,. Aquaporin-1 water channel protein in lung: ontogeny, steroid-induced expression, and distribution in rat. J Clin Invest. 1996; 97: 2183-2191.
14. Jiang J, Hu J, Bai C,. Role of aquaporin and sodium channel in pleural water movement. Respir Physiol Neurobiol. 2003; 139: 83-88.
15. Song Y, Yang B, Matthay MA, Ma T, Verkman AS,. Role of aquaporin water channels in pleural fluid dynamics. Am J Physiol Cell Physiol. 2000; 279: C1744-C1750.
16. Verkman AS, Hara-Chikuma M, Papadopoulos MC,. Aquaporins-new players in cancer biology. J Mol Med. 2008; 86: 523-529.
17. Yool AJ, Brown EA, Flynn GA,. Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer. Clin Exp Pharmacol Physiol. 2010; 37: 403-409.
18. Verkman AS,. Applications of aquaporin inhibitors. Drug News Perspect. 2001; 14: 412-420.
19. Yool AJ, Brokl OH, Pannabecker TL, Dantzler WH, Stamer WD,. Tetraethylammonium block of water flux in Aquaporin-1 channels expressed in kidney thin limbs of Henle's loop and a kidney-derived cell line. BMC Physiol. 2002; 2: 4.
20. Roe OD, Anderssen E, Helge E, et al. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One. 2009; 4: e6554.
21. Gordon GJ,. Expression profiling of malignant mesothelioma. Accessed June 6, 2011.
22. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: International Agency for Research on Cancer; 2004.
23. Klebe S, Nurminen M, Leigh J, Henderson DW,. Diagnosis of epithelial mesothelioma using tree-based regression analysis and a minimal panel of antibodies. Pathology. 2009; 41: 140-148.
24. Kao SC, Lee K, Armstrong NJ, et al. Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology. 2011; 43: 128-132.
25. Llewellyn-Smith IJ, Minson JB,. Complete penetration of antibodies into vibratome sections after glutaraldehyde fixation and ethanol treatment: light and electron microscopy for neuropeptides. J Histochem Cytochem. 1992; 40: 1741-1749.
26. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2011; 16: 5805-5813.
27. Kao SCH, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in malignant mesothelioma in patients undergoing extrapleural pneumonectomy. J Thorac Oncol. 2011; doi:10.1097/JTO.0b013e31822a3740.
28. Schemper M, Henderson R,. Predictive accuracy and explained variation in Cox regression. Biometrics. 2000; 56: 249-255.
29. Lusa L, Miceli R, Marian L,. Estimation of predictive accuracy in survival analysis using R and S-PLUS. Comput Methods Programs Biomed. 2007; 87: 132-137.
30. Dunkler D, Michiels S, Schemper M,. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer. 2007; 43: 745-751.
31. Montanaro F, Rosato R, Gangemi M, et al. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer. 2009; 124: 201-207.
32. Reck M, Stahel RA, von Pawel J, et al. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. Respir Med. 2010; 104: 142-148.
33. Steele JP,. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am. 2005; 19: 1041-1052, vi.
34. Gaafar R, Bahnassy A, Abdelsalam I, et al. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer. 2011; 70: 43-50.
35. Righi L, Papotti MG, Ceppi P, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010; 28: 1534-1539.
36. Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res. 2011; 17: 2581-2590.
37. Kao SCH, Klebe S, Henderson DW, et al. Protein expression of excision repair cross complementation group 1 and thymidylate synthase in malignant pleural mesothelioma patients undergoing extrapleural pneumonectomy. Presented at the 14th World Conference on Lung Cancer; July 3-7, 2011; Amsterdam, Netherlands. Poster P3.307.
38. Vacca A, Frigeri A, Ribatti D, et al. Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. Br J Haematol. 2001; 113: 415-421.